Palmitoylethanolamide/Baicalin Supplementation and Changes in Pain and Sudomotor Function in Type 2 Diabetes: A Retrospective Matched Real-World Cohort Study
Observational studyHumansWith baicalin
This study tested palmitoylethanolamide together with baicalin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 96 patients with type 2 diabetes and nerve damage, in two matched groups of 48
- Dose used in the study
- 600 mg of palmitoylethanolamide with 250 mg of baicalin, twice a day (Neuridase). The comparison group took no supplement.
- Duration
- 6 months
- What was measured
- Nerve pain on a visual analogue scale and a skin conductance test of small nerve function
What the authors reported
The median pain score fell from 5.5 to 3.0 in the supplement group (p < 0.0001) and did not change in the comparison group, which started at 2.0. Pain worsened in 31.3% of the comparison group compared with none of the supplement group (p = 0.00022). Skin conductance in the hands rose from 53.0 to 60.0 microsiemens in the supplement group (p = 0.035) and declined across all three sudomotor measures in the comparison group.
Limits of this study
A retrospective study of patient records. The groups differed at the start: the supplement group had much higher pain scores, so regression to the mean cannot be excluded, as the authors state. They also name confounding, a single centre and expectation bias. The publication fee was paid by the product's manufacturer, Enfarma.
Source
PubMed 42356281 · doi:10.3390/nu18121894
Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.